Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Causes and pathophysiology of the sideroblastic anemias

Sylvia S Bottomley, MD
Section Editor
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD


Sideroblastic anemias are anemias in which ring sideroblasts are present on the bone marrow aspirate smear stained for iron with Prussian blue. Ring sideroblasts are found in diverse circumstances, which underscores a broad spectrum of causes of sideroblastic anemia, both inherited and acquired (table 1). Understanding the causative mechanisms is useful for predicting the disease course and guiding therapy, which differ for the various sideroblastic anemia forms.

This topic review discusses the recognized congenital and acquired causes of the sideroblastic anemias and their pathophysiology. The clinical presentations and diagnostic testing for specific forms of sideroblastic anemia, and our approach to patient management, are presented in detail separately. (See "Sideroblastic anemias: Diagnosis and management".)


The conventional classification of the sideroblastic anemias is structured on whether the cause is congenital (inherited) or acquired, followed by listing specific genetic defects or environmental factors (table 1). In searching for the cause it can also be helpful to note whether the anemia is microcytic or normocytic/macrocytic (table 2).

Congenital sideroblastic anemias — Congenital sideroblastic anemias are caused by a germline mutation (or other genetic alteration) in a nuclear or mitochondrial gene (or genes). For a number of forms, underlying defects have been established at the molecular level, as illustrated in the diagram (figure 1). However, approximately one-third of cases do not have an identifiable genetic defect as of yet [1-3]. The causative defects for these patients are actively being sought in research laboratories.

The congenital sideroblastic anemias can be subdivided into syndromic and non-syndromic forms (table 1), by their mode of inheritance (X-linked, autosomal recessive, or mitochondrial) or according to red blood cell size (microcytic or normocytic-to-macrocytic) (table 2). The majority appear as non-syndromic, with isolated anemia and ring sideroblasts in the bone marrow. The syndromic forms, which affect other organ systems, are very uncommon.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Fri Mar 17 00:00:00 GMT+00:00 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010; 54:273.
  2. Liu G, Guo S, Kang H, et al. Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship. Haematologica 2013; 98:e158.
  3. Ducamp S, Kannengiesser C, Touati M, et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011; 32:590.
  4. Bottomley SS. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 13th ed, Greer JP, Arber DA, Glader B, et al. (Eds), Lippincott, Williams and Wilkins, Philadelphia 2014. p.643.
  5. Nakajima O, Takahashi S, Harigae H, et al. Heme deficiency in erythroid lineage causes differentiation arrest and cytoplasmic iron overload. EMBO J 1999; 18:6282.
  6. Nakajima O, Okano S, Harada H, et al. Transgenic rescue of erythroid 5-aminolevulinate synthase-deficient mice results in the formation of ring sideroblasts and siderocytes. Genes Cells 2006; 11:685.
  7. Kaneko K, Furuyama K, Fujiwara T, et al. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia. Haematologica 2014; 99:252.
  8. Campagna DR, de Bie CI, Schmitz-Abe K, et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol 2014; 89:315.
  9. Bekri S, May A, Cotter PD, et al. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood 2003; 102:698.
  10. Cox TC, Bawden MJ, Abraham NG, et al. Erythroid 5-aminolevulinate synthase is located on the X chromosome. Am J Hum Genet 1990; 46:107.
  11. Bishop DF, Henderson AS, Astrin KH. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics 1990; 7:207.
  12. Aivado M, Gattermann N, Rong A, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis 2006; 37:40.
  13. Rose C, Callebaut I, Pascal L, et al. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia. Br J Haematol 2016.
  14. Bottomley SS, Wise PD, Wasson EG, et al. X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation. Am J Hum Genet 1998; 63(Suppl):A352.
  15. Cazzola M, May A, Bergamaschi G, et al. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood 2000; 96:4363.
  16. Guernsey DL, Jiang H, Campagna DR, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 2009; 41:651.
  17. Kannengiesser C, Sanchez M, Sweeney M, et al. Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematologica 2011; 96:808.
  18. Ye H, Jeong SY, Ghosh MC, et al. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest 2010; 120:1749.
  19. Wingert RA, Galloway JL, Barut B, et al. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 2005; 436:1035.
  20. Camaschella C, Campanella A, De Falco L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110:1353.
  21. Liu G, Guo S, Anderson GJ, et al. Heterozygous missense mutations in the GLRX5 gene cause sideroblastic anemia in a Chinese patient. Blood 2014; 124:2750.
  22. Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, et al. Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood 2015; 126:2734.
  23. Scott AJ, Ansford AJ, Webster BH, Stringer HC. Erythropoietic protoporphyria with features of a sideroblastic anaemia terminating in liver failure. Am J Med 1973; 54:251.
  24. Rademakers LH, Koningsberger JC, Sorber CW, et al. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest 1993; 23:130.
  25. Bottomley SS, Tanaka M, Everett MA. Diminished erythroid ferrochelatase activity in protoporphyria. J Lab Clin Med 1975; 86:126.
  26. Pagon RA, Bird TD, Detter JC, Pierce I. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet 1985; 22:267.
  27. Pondarre C, Campagna DR, Antiochos B, et al. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 2007; 109:3567.
  28. Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 2000; 96:3256.
  29. Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999; 8:743.
  30. Maguire A, Hellier K, Hammans S, May A. X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L. Br J Haematol 2001; 115:910.
  31. D'Hooghe M, Selleslag D, Mortier G, et al. X-linked sideroblastic anemia and ataxia: a new family with identification of a fourth ABCB7 gene mutation. Eur J Paediatr Neurol 2012; 16:730.
  32. Casas KA, Fischel-Ghodsian N. Mitochondrial myopathy and sideroblastic anemia. Am J Med Genet A 2004; 125A:201.
  33. Bykhovskaya Y, Casas K, Mengesha E, et al. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet 2004; 74:1303.
  34. Riley LG, Rudinger-Thirion J, Schmitz-Abe K, et al. LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure. JIMD Rep 2016; 28:49.
  35. Burrage LC, Tang S, Wang J, et al. Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G>A) in the mitochondrial encoded ATP6 gene. Mol Genet Metab 2014; 113:207.
  36. Lichtenstein DA, Crispin AW, Sendamarai AK, et al. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood 2016; 128:1913.
  37. Riley LG, Menezes MJ, Rudinger-Thirion J, et al. Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia. Orphanet J Rare Dis 2013; 8:193.
  38. Wiseman DH, May A, Jolles S, et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood 2013; 122:112.
  39. Chakraborty PK, Schmitz-Abe K, Kennedy EK, et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 2014; 124:2867.
  40. DeLuca AP, Whitmore SS, Barnes J, et al. Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis. Hum Mol Genet 2016; 25:44.
  41. Rötig A, Bourgeron T, Chretien D, et al. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 1995; 4:1327.
  42. Bader-Meunier B, Miélot F, Breton-Gorius J, et al. Hematologic involvement in mitochondrial cytopathies in childhood: a retrospective study of bone marrow smears. Pediatr Res 1999; 46:158.
  43. Bergmann AK, Sahai I, Falcone JF, et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009; 155:888.
  44. Labay V, Raz T, Baron D, et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999; 22:300.
  45. Fleming JC, Tartaglini E, Steinkamp MP, et al. The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nat Genet 1999; 22:305.
  46. Diaz GA, Banikazemi M, Oishi K, et al. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet 1999; 22:309.
  47. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.
  48. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365:1384.
  49. Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 2015; 126:233.
  50. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol 2015; 90:549.
  51. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.
  52. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119:569.
  53. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26:542.
  54. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119:3211.
  55. Broséus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27:1826.
  56. Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120:3173.
  57. Sarkany RP, Ross G, Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol 2006; 155:464.
  58. Gattermann N, Retzlaff S, Wang YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997; 90:4961.
  59. Savage D, Lindenbaum J. Anemia in alcoholics. Medicine (Baltimore) 1986; 65:322.
  60. Bottomley SS. Sideroblastic anaemia. In: Iron in Biochemistry and Medicine II, Jacobs A, Worwood M (Eds), Academic Press, London 1980. p.363.
  61. Saini N, Jacobson JO, Jha S, et al. The perils of not digging deep enough--uncovering a rare cause of acquired anemia. Am J Hematol 2012; 87:413.
  62. Willekens C, Dumezy F, Boyer T, et al. Linezolid induces ring sideroblasts. Haematologica 2013; 98:e138.
  63. Ok CY, Medeiros LJ, Hu Y, et al. Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leuk Res 2011; 35:1605.
  64. O'Brien H, Amess JA, Mollin DL. Recurrent thrombocytopenia, erythroid hypoplasia and sideroblastic anaemia associated with hypothermia. Br J Haematol 1982; 51:451.
  65. Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am 2014; 28:653.
  66. Fleming MD. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology Am Soc Hematol Educ Program 2011; 2011:525.
  67. Bottomley SS. The spectrum and role of iron overload in sideroblastic anemia. Ann N Y Acad Sci 1988; 526:331.
  68. May A, de Souza P, Barnes K, et al. Erythroblast iron metabolism in sideroblastic marrows. Br J Haematol 1982; 52:611.
  69. Levi S, Corsi B, Bosisio M, et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001; 276:24437.
  70. Cazzola M, Invernizzi R, Bergamaschi G, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101:1996.
  71. Rouault TA. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech 2012; 5:155.
  72. Astner I, Schulze JO, van den Heuvel J, et al. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J 2005; 24:3166.
  73. Shoolingin-Jordan PM, Al-Daihan S, Alexeev D, et al. 5-Aminolevulinic acid synthase: mechanism, mutations and medicine. Biochim Biophys Acta 2003; 1647:361.
  74. Harigae H, Furuyama K, Kudo K, et al. A novel mutation of the erythroid-specific gamma-Aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia. Am J Hematol 1999; 62:112.
  75. Cox TC, Bottomley SS, Wiley JS, et al. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med 1994; 330:675.
  76. Lunetti P, Damiano F, De Benedetto G, et al. Characterization of Human and Yeast Mitochondrial Glycine Carriers with Implications for Heme Biosynthesis and Anemia. J Biol Chem 2016; 291:19746.
  77. Holme SA, Worwood M, Anstey AV, et al. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007; 110:4108.
  78. Fratz-Berilla EJ, Breydo L, Gouya L, et al. Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. Biochim Biophys Acta 2017; 1863:428.
  79. Yunis AA, Salem Z. Drug-induced mitochondrial damage and sideroblastic change. Clin Haematol 1980; 9:607.
  80. Stehling O, Lill R. The role of mitochondria in cellular iron-sulfur protein biogenesis: mechanisms, connected processes, and diseases. Cold Spring Harb Perspect Biol 2013; 5:a011312.
  81. Suzuki T, Nagao A, Suzuki T. Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases. Annu Rev Genet 2011; 45:299.
  82. Gattermann N. Iron rusting in the mitochondria? Blood 2016; 128:1907.
  83. Patton JR, Bykhovskaya Y, Mengesha E, et al. Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem 2005; 280:19823.
  84. Liwak-Muir U, Mamady H, Naas T, et al. Impaired activity of CCA-adding enzyme TRNT1 impacts OXPHOS complexes and cellular respiration in SIFD patient-derived fibroblasts. Orphanet J Rare Dis 2016; 11:79.
  85. Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294:93.
  86. Malcovati L, Cazzola M. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. Br J Haematol 2016; 174:847.
  87. Dolatshad H, Pellagatti A, Liberante FG, et al. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia 2016; 30:2322.
  88. Nikpour M, Scharenberg C, Liu A, et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 2013; 27:889.
  89. Boultwood J, Pellagatti A, Nikpour M, et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008; 3:e1970.
  90. Dolatshad H, Pellagatti A, Fernandez-Mercado M, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia 2015; 29:1092.
  91. Boros LG, Steinkamp MP, Fleming JC, et al. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood 2003; 102:3556.
  92. Abboud MR, Alexander D, Najjar SS. Diabetes mellitus, thiamine-dependent megaloblastic anemia, and sensorineural deafness associated with deficient alpha-ketoglutarate dehydrogenase activity. J Pediatr 1985; 107:537.
  93. Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985; 65:238.
  94. Williams DM, Loukopoulos D, Lee GR, Cartwright GE. Role of copper in mitochondrial iron metabolism. Blood 1976; 48:77.
  95. Peled T, Glukhman E, Hasson N, et al. Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells. Exp Hematol 2005; 33:1092.
  96. Matthes TW, Meyer G, Samii K, Beris P. Increased apoptosis in acquired sideroblastic anaemia. Br J Haematol 2000; 111:843.
  97. Hellström-Lindberg E, Schmidt-Mende J, Forsblom AM, et al. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001; 112:714.
  98. Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106:247.
  99. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol 2016; 172:512.
  100. Ambaglio I, Malcovati L, Papaemmanuil E, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica 2013; 98:420.
  101. Peto TE, Pippard MJ, Weatherall DJ. Iron overload in mild sideroblastic anaemias. Lancet 1983; 1:375.
  102. Cazzola M, Barosi G, Bergamaschi G, et al. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. Br J Haematol 1983; 54:649.
  103. Bottomley SS. Iron overload in sideroblastic and other non-thalassemic anemias. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment, Barton JC, Edwards CQ (Eds), Cambridge University Press, Cambridge 2000. p.442.
  104. Marcus RE. Iron overload in mild sideroblastic anaemia. Lancet 1983; 1:1276.
  105. Bottomley SS. Sideroblastic anemia: Death from iron overload. Hosp Pract 1991; 26(suppl 3):55.
  106. Heller T, Höchstetter V, Basler M, Borck V. [Vitamin B6-sensitive hereditary sideroblastic anemia]. Dtsch Med Wochenschr 2004; 129:141.
  107. Yaouanq J, Grosbois B, Jouanolle AM, et al. Haemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia. Lancet 1997; 349:1475.
  108. Cotter PD, May A, Li L, et al. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood 1999; 93:1757.
  109. Nearman ZP, Szpurka H, Serio B, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007; 82:1076.
  110. French TJ, Jacobs P. Sideroblastic anaemia associated with iron overload treated by repeated phlebotomy. S Afr Med J 1976; 50:594.
  111. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94:288.
  112. Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 1988; 25:282.
Topic Outline